The Trump administration didn’t move forward with a highly anticipated decision on whether costly obesity drugs would be covered by Medicare in its annual regulatory update Friday.

Trump’s predecessor, Joe Biden, proposed a rule in late November after Trump won re-election that would have extended ...

The Trump administration has chosen not to finalize a rule proposed by the Biden administration that would have allowed ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Trump officials reject Medicare coverage ...

The Biden administration proposal would have significantly expanded access to obesity to millions of Americans but would have cost the government billions.

The proposal would have enabled more Americans to afford new medications in the GLP-1 class that have been shown to reduce weight.

Administration officials reversed a decision made during the Biden presidency that would have given millions of people access ...

Trump administration rejects a Biden plan to expand Medicare coverage of weight-loss drugs such as Zepbound and Wegovy.

The Centers for Medicare & Medicaid Services said on Friday it did not move forward with a proposal put forth by the Biden ...

Shares of Eli Lilly, the seller of Zepbound, were down 2.7% to $718.50 after the close on Friday. Novo Nordisk, the maker of Wegovy, saw its stock decline 1.4% to $61.67. Shares of Hims & Hers, a ...

Jim Cramer in a latest program on CNBC urged investors to start accepting the reality of the new economic system under ...

The telehealth company Hims & Hers is adding Zepbound and generic liraglutide to its offering of weight-loss drugs.